Posted by Michael Wonder on 16 Feb 2022
European Commission approves Oxbryta (voxelotor) for the treatment of haemolytic anaemia in patients with sickle cell disease age 12 years and older
16 February 2022 - The first sickle haemoglobin polymerisation inhibitor approved in Europe, Oxbryta increases haemoglobin levels and reduces sickling and haemolysis – the cause of long-term complications of sickle cell disease
Global Blood Therapeutics today announced the European Commission has granted Marketing Authorization for Oxbryta (voxelotor) for the treatment of haemolytic anaemia due to sickle cell disease in adult and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea).
